SCHEMBL1025540

SCHEMBL1025540

C#Cc1cncc(NC(=O)O)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.40
EGLN1 Q9GZT9 1/20 0.37
MAPT P10636 2/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
GBA1 P04062 1/20 0.36
CYP2A6 P11509 1/20 0.36
GRM5 P41594 1/20 0.36
CNR1 P21554 1/20 0.34
IDH1 O75874 1/20 0.33
PDGFRB P09619 2/20 0.33
KDR P35968 2/20 0.33
KCNH2 Q12809 1/20 0.33
SCN10A Q9Y5Y9 1/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
KMT2A Q03164 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
GPR35 Q9HC97 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16733398 0.84 DYRK1A (0.53) DYRK1AMAPTKDM4EALDH1A1MEN1
SCHEMBL28723840 0.82 GPR35 (0.47) MAPTALDH1A1GRM5KCNH2SCN10A
SCHEMBL3802380 0.80 MEN1 (0.38) DYRK1AEGLN1MAPTALDH1A1GBA1
SCHEMBL6035211 0.80 GRM5 (0.45) MAPTKDM4EALDH1A1GRM5PDGFRB
SCHEMBL1025139 0.77 MAPT (0.39) DYRK1AMAPTKDM4EALDH1A1PDGFRB
SCHEMBL12209857 0.77 NAMPT (0.45) DYRK1A
SCHEMBL4638868 0.74 RET (0.41) MAPTPDGFRBKDR
SCHEMBL3484331 0.73 KDM4E (0.40) DYRK1AMAPTKDM4EALDH1A1CNR1
SCHEMBL1531663 0.73 HCAR2 (0.53) MAPTKDM4EALDH1A1SCN10A
SCHEMBL1025225 0.73 MEN1 (0.56) MAPTALDH1A1IDH1MEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
US-8765727-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-07-01 US disclosed
US-20110251215-A9 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2011-10-13 US disclosed
EP-2274288-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS Incyte Corporation (US) 2011-01-19 EP disclosed
US-20100190804-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2010-07-29 US disclosed
WO-2010085597-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2010-07-29 WO disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed
WO-2009132202-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS JAK2, JAK1, ALK DYRK1A 1435/4885EGLN1 1696/4885MAPT 3239/4885
US-20110251215-A9 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS JAK2, JAK1, ALK DYRK1A 1435/4885EGLN1 1696/4885MAPT 3239/4885
US-20100190804-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS JAK2, JAK1, ALK DYRK1A 1435/4885EGLN1 1696/4885MAPT 3239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.